Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients

The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against FVIII/FIX face an increased risk of bleeding, and the likelihood of early development of progressive arthropathy, alongside hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ljung, Rolf, Auerswald, Guenter, Benson, Gary, Dolan, Gerry, Duffy, Anne, Hermans, Cedric, Jiménez‐Yuste, Victor, Lambert, Thierry, Morfini, Massimo, Zupančić‐Šalek, Silva, Santagostino, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936224/
https://www.ncbi.nlm.nih.gov/pubmed/30411401
http://dx.doi.org/10.1111/ejh.13193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936224/
https://www.ncbi.nlm.nih.gov/pubmed/30411401
http://dx.doi.org/10.1111/ejh.13193

Ejemplares similares